Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290998 | 0.85 | LPL (0.31) | LPLLIPG | |
| SCHEMBL29427144 | 0.84 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL26631296 | 0.84 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1494491 | 0.83 | CA1 (0.37) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30345372 | 0.83 | CA1 (0.37) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29170643 | 0.83 | LPL (0.35) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16532525 | 0.83 | LPL (0.35) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20347065 | 0.82 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16815511 | 0.82 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL28937486 | 0.80 | LPL (0.35) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-114096533-B | Tri-ring compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112119065-B | Benzodiazepine compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117229215-A | Biaryl compound, pharmaceutical composition containing biaryl compound, preparation method and application of biaryl compound | 四川科伦博泰生物医药股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-112839931-B | 1,2,3, 4-tetrahydroquinoxaline derivative, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-114096525-B | Biaryl compound, pharmaceutical composition containing biaryl compound, preparation method and application of biaryl compound | 四川科伦博泰生物医药股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3008057-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | Amgen Inc. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160046626-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2016-02-18 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667606-B2 | Thyromimetics | TPO, TSHR, TTR | LPL 2416/4885LIPG 3452/4885CA1 229/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | LPL 2/4885LIPG 17/4885CA1 2762/4885 |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | LPL 4701/4885LIPG 4204/4885CA1 768/4885 |
| US-20160046626-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | LPL 4701/4885LIPG 4204/4885CA1 768/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LPL 2/4885LIPG 8/4885CA1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.